Replies to post #11823 on Momenta Pharmaceuticals, Inc. (MNTA)

[jq1234]

I don't think it would affect eventual approval, delay is certainly possible because FDA ultimately has to address some not all of the points Teva raised in eventual approval document.

[biotech_researcher]

This is stunningly complex. Seems to me that if the worst case scenario is a 2015 approval at a 75% possibility, then this is a tolerable risk at this point.